

References

S-32

1. Seftel A, Kathrins M, Niederberger C. Critical update of the 2010 Endocrine Society clinical practice guidelines for male hypogonadism: A systematic analysis. *Mayo Clin Proc.* 2015;90(8):1104-1115.
2. Testosterone. Micromedex 2.0. Truven Health Analytics, Inc. Greenwood Village, CO.
3. Hackett G. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. *BJU International.* 2016;118: 804-813.
4. Dimopoulou C. EMAS position statement: Testosterone replacement therapy in the aging male. *Maturitas.* 2015: 1-7.
5. Cui Y, Zong H, Yan H, Zang H. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. *Prostate Cancer Prostatic Dis.* Jun 2014;17(2):132-143.
6. Kathrins M, Doersch K, Nimeh T, Canto A, Niederberger C, et al. The relationship between testosterone-replacement therapy and lower urinary tract symptoms: a systematic review. *Urology.* 2015; 88:22-32.
7. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, et al. Testosterone therapy in men with hypogonadism: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab.* May 1 2018;103(5):1715-1744.